Your session is about to expire
← Back to Search
This trial is testing the safety and efficacy of a new drug combination to treat small cell lung cancer.
- Lung Cancer
- Bladder Cancer
- Small Cell Lung Cancer
- Prostate Cancer
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a Location
Who is running the clinical trial?
- You are allergic to the study treatments.You are currently taking part in another study for an experimental medication.You don't necessarily need to have a measurable disease to participate in Phase I.You agree to provide a tissue sample from a previous medical procedure for research purposes, if it is available.You have had tumors in your brain that were treated with surgery or radiation, but they must have been stable for at least 2 weeks and you should not be taking certain medications that could interact with the study drug.
- Group 1: 2/Phase II
- Group 2: 1/Phase I
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this a cutting-edge research project?
"Since 2005, EP0057 has been the focus of numerous clinical trials. The initial trial was sponsored by AstraZeneca and included 98 participants - leading to its Phase 1 drug approval. Currently there are 188 active studies for this medicine occurring in 59 countries across 1468 cities."
Has EP0057 been the subject of prior scientific inquiry?
"Presently, 188 clinical trials are being conducted in order to research EP0057. Out of those studies, 27 have advanced past the third phase. Despite most of these trials taking place near Houston, Texas, there are 9250 different sites around the world that provide access to this medical treatment."
How many participants are the maximum allowed to join this experiment?
"Absolutely. Data hosted on clinicaltrials.gov attests to the fact that this medical study is still searching for participants, having been initially posted on May 9th 2016 and recently modified in November 16th 2022. 123 patients from a single trial site are needed to complete the trail."
What is the primary aim of this research endeavor?
"This 28-day medical trial will assess the overall response rate of EP0057 plus olaparib in patients with urothelial carcinoma. Secondary objectives include exploring further safety combination effects, determining duration of response and PSA on mCRPC expansion cohort, and noting any adverse event frequency associated with the study regimen."
Are there any vacancies remaining for potential participants of this study?
"Affirmative. Information housed on clinicaltrials.gov reveals that this medical research is presently seeking participants, with the initial post date being May 9th 2016 and latest update occurring November 16th 2022. The team requires 123 subjects from a solitary site to join in the trial."
Share this study with friends